Developing targeted therapies for kidney diseases using nanoparticles
Nanoparticle-targeted therapeutic development for glomerular diseases
This study is working on new treatments for kidney diseases, especially for those that can lead to serious kidney problems, and it's aimed at helping people, particularly in African American communities, by using tiny particles to deliver medicine right to the kidneys.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11002161 on NIH RePORTER |
What this research studies
This research focuses on creating innovative therapies specifically designed to target kidney diseases, particularly glomerular diseases that can lead to end-stage kidney disease (ESKD). The project involves a collaborative team of experts in biomedical engineering, cell biology, nephrology, and pharmacology, who aim to translate laboratory findings into clinical applications. By utilizing biocompatible nanoparticles, the research seeks to improve the delivery of treatments directly to the affected kidney cells, potentially reducing the burden of chronic kidney disease and its complications. The study also addresses health disparities, particularly among African American populations who are disproportionately affected by these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from chronic kidney disease or those at risk of progressing to end-stage kidney disease, particularly within the African American community.
Not a fit: Patients with kidney diseases not related to glomerular conditions or those who do not belong to the targeted demographic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for kidney diseases, improving patient outcomes and reducing the need for dialysis or transplants.
How similar studies have performed: Previous research has shown promise in using targeted nanoparticle therapies for various diseases, indicating potential success for this novel approach in kidney disease treatment.
Where this research is happening
New York, United States
- City College of New York — New York, United States (Active)
Researchers
- Principal investigator: Williams, Ryan Martin — City College of New York
- Study coordinator: Williams, Ryan Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.